Arrowhead has issued valuation report on CombiGene
A Due Diligence and Valuation Report on CombiGene AB (publ) was published December 14th 2015 by the New York based financial services firm Arrowhead Business and Investment Decisions, LLC (ABID). The report was also mentioned in a More from the Company newsletter issued already December 4th.
The analysis was commissioned and paid by CombiGene and was based on the collection and analysis of public information and public company disclosures. The report has not been reviewed for its accuracy or approved by any financial regulatory authority in the US or elsewhere. Arrowhead is an independent research firm and is not a registered broker-dealer neither with FINRA nor the SEC. The release was made at www.abid.co/AKTO.COMBI on Monday December 14th at 9:05 AM NY time (3:05 PM Swedish time) and a link to the report will be posted at CombiGene’s website.
“We chose a US firm for this analysis in order to get a wider international distribution of the report, and the price wasn’t higher than if a similar report would have been made for example in Sweden” says CEO Bengt Westrin and continues: “Before commissioning Arrowhead for this task, we reviewed a number of other life science company analyses made by Arrowhead and got a good impression of the quality of their work”.
"We are pleased to announce the initiation of coverage on CombiGene, which we plan to update regularly. We look forward to developing awareness of CombiGene within the international biotech investment community. We anticipate as part of this commitment also making available to our network information and analytical material on other companies within the vibrant Scandinavian biotech industry." says Mr. Daniel Renaud, Managing Director of Arrowhead Business and Investment Decisions, LLC.
For further information:
CombiGene AB (publ)
Bengt Westrin, CEO
Tel: +46 70 265 48 62
email: bengt.westrin@combigene.com
About Arrowhead Business and Investment Decisions
Arrowhead Business and Investment Decisions, LLC is a New York City based provider of equity research and investor relations services. Arrowhead covers several industries and sectors, from healthcare to technology, materials and energy. Arrowhead also operates the financial information platform www.abid.co. Arrowhead’s investor network is composed of recognized pension funds, mutual funds, hedge funds, private equity funds, investment banks, brokerages, venture capital funds and family offices. Further information can be found at www.arrowheadbid.com.
About CombiGene AB
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. Current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com .
MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com.